A Multicenter, Randomized, Double-blind, Placebo-controlled Trial on the Treatment of Hypertensive Intracerebral Hemorrhage With Naoxuekang Dropping Pills

Inclusion criteria

• Meets the diagnostic criteria for hypertensive intracerebral hemorrhage.
• Able to cooperate with a head MRI examination and has imaging manifestations of cerebral small vessel disease (CSVD) (Staals total CSVD burden score ≥ 1).
• Supratentorial hemorrhage (volume ≤ 30ml) or infratentorial hemorrhage (volume ≤ 10ml).
• Within 7 days of symptom onset.
• NIHSS score ≤ 25.
• GCS score ≥ 8.
• Age between 18 and 80 years (inclusive).
• Any gender

Exclusion criteria

• Primary intraventricular hemorrhage.
• Spontaneous intracerebral hemorrhage due to other causes or secondary intracerebral hemorrhage (e.g., from trauma, vascular malformations, coagulation disorders, hematological diseases, systemic diseases, or tumors).
• Planned surgical intervention (including craniotomy for hematoma evacuation, minimally invasive hematoma removal, or ventricular puncture).
• Patients with active peptic ulcer, bleeding, or other clear tendency for rebleeding.
• Patients with severe hepatic or renal dysfunction (Severe hepatic dysfunction: ALT or AST > 3 times the upper limit of normal; Severe renal dysfunction: Serum creatinine > 2 times the upper limit of normal).
• Suffering from other life-threatening severe diseases with an expected survival time of less than 1 year.
• Known allergy to any component of the study drug.
• Pregnant women, women planning pregnancy, or lactating women.
• Participating in another interventional clinical trial.